EUVIMEDEUVIMED entdecken
Crossref

Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression

Yusuke Aoki, Yutaro Kubota, Noriyuki Masaki, Koya Obara, Yasunori Tome, Michael Bouvet, Kotaro Nishida, Robert M Hoffman

Anticancer Research · 2024

DOI: 10.21873/anticanres.17090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yusuke Aoki und 7 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc, San Diego, CA, U.S.A.; yaoki0630@gmail.com. Hauptthemen laut MEDLINE: Osteosarcoma, Methotrexate, Tetrahydrofolate Dehydrogenase, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaMethotrexateTetrahydrofolate DehydrogenaseDrug Resistance, NeoplasmTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-mycHumansAnimalsCell Line, TumorMiceXenograft Model Antitumor AssaysBone NeoplasmsGene AmplificationSignal TransductionMice, NudeAntimetabolites, Antineoplastic

Stichwörter der Autor:innen

AKTDHFROsteosarcomaPI3Kc-MYCmTORmalignancymethotrexatenude miceresistancetumor suppressor

Substanzen

MethotrexateTetrahydrofolate DehydrogenaseTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-mycMTOR protein, humanAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • AntiCancer Inc, San Diego, CA, U.S.A.; yaoki0630@gmail.com.
  • Department of Surgery, University of California, San Diego, La Jolla, CA, U.S.A.
  • Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan.
  • AntiCancer Inc, San Diego, CA, U.S.A.
  • Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan yastome@med.u-ryukyu.ac.jp.
  • AntiCancer Inc, San Diego, CA, U.S.A.; all@anticancer.com.

Zitieren

APA

Aoki, Y., Kubota, Y., Masaki, N., Obara, K., Tome, Y., Bouvet, M., Nishida, K., & Hoffman, R. M. (2024). Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. Anticancer Research. https://doi.org/10.21873/anticanres.17090

Vancouver

Aoki Y, Kubota Y, Masaki N, Obara K, Tome Y, Bouvet M, et al. Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. Anticancer Research. 2024. doi:10.21873/anticanres.17090

BibTeX
@article{Aoki2024,
  author = {Aoki, Yusuke and Kubota, Yutaro and Masaki, Noriyuki and Obara, Koya and Tome, Yasunori and Bouvet, Michael and Nishida, Kotaro and Hoffman, Robert M},
  title = {Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17090}
}
Kostenlos starten →